Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01737814 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
A Phase 3 study, sponsored by Mast Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 388
- Enrollment target
NCT01737814 is a Phase 3 study that has completed, run by Mast Therapeutics. The registered enrollment target is 388 participants.
The verdict
NCT01737814, a Phase 3 study, has completed, sponsored by Mast Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 388 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether MST-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether MST-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive MST-188 to those who do not receive MST-188.
Interventions
- DRUG Saline
- DRUG MST-188
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 388 participants |
| Start Date | 2013-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01737814
The ClinicalTrials.gov registry entry for NCT01737814 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 388 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mast Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT01737814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01737814 about?
NCT01737814 is a clinical study titled "Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)". The purpose of this study is to evaluate whether MST-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether MST-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this ...
What is the current status of trial NCT01737814?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 388 participants. The study started on 2013-05.
What interventions are being tested in trial NCT01737814?
The interventions under investigation include: Saline (DRUG), MST-188 (DRUG).
Who is sponsoring clinical trial NCT01737814?
This trial is sponsored by Mast Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.